PURPOSE: The aim of this study is to investigate the expression of CK2 subunits and CK2 effects on NF-kappaB-mediated and TP53-mediated signal activation and gene expression, the malignant phenotype, and chemosensitivity in head and neck squamous cell carcinoma (HNSCC) in vitro and in vivo. EXPERIMENTAL DESIGN: Protein expression of CK2 subunits was investigated by Western blot and immunohistochemistry. CK2 subunits were knocked down by small interfering RNA, and NF-kappaB activation was examined using DNA binding, Western blot, and luciferase reporter assays. Gene expression was measured by quantitative reverse transcription-PCR. Cell growth, survival, motility, and sensitivity to cisplatin were measured by MTT, flow cytometry, and migration assays. In vivo targeting of CK2alpha/alpha' in HNSCC xenograft models was achieved using anti-CK2alpha/alpha' oligodeoxynucleotide encapsulated in sub-50-nm tenfibgen nanocapsules. RESULTS: CK2 subunit proteins were overexpressed in HNSCC lines and tissues. Knockdown of CK2 subunits differentially inhibited IkappaBalpha degradation, NF-kappaB nuclear localization, phosphorylation, DNA binding, and reporter activity. CK2 subunits modulated gene expression and the malignant phenotype involved in cell cycle and migration, whereas CK2alpha is critical to promote proliferation, antiapoptosis, and cisplatin resistance in vitro. Furthermore, in vivo delivery of anti-CK2alpha/alpha' oligodeoxynucleotide nanocapsules significantly suppressed tumor growth in HNSCC xenograft models, in association with modulation of CK2 and NF-kappaB regulated molecules, TP53 family proteins, and induction of apoptosis. CONCLUSIONS: Our study reveals a novel role of CK2 in coregulating NF-kappaB activation, TP53/p63 expression, and downstream gene expression. Downregulation of CK2 in HNSCC models in vitro and in vivo shows antitumor effects as well as sensitization to cisplatin.
PURPOSE: The aim of this study is to investigate the expression of CK2 subunits and CK2 effects on NF-kappaB-mediated and TP53-mediated signal activation and gene expression, the malignant phenotype, and chemosensitivity in head and neck squamous cell carcinoma (HNSCC) in vitro and in vivo. EXPERIMENTAL DESIGN: Protein expression of CK2 subunits was investigated by Western blot and immunohistochemistry. CK2 subunits were knocked down by small interfering RNA, and NF-kappaB activation was examined using DNA binding, Western blot, and luciferase reporter assays. Gene expression was measured by quantitative reverse transcription-PCR. Cell growth, survival, motility, and sensitivity to cisplatin were measured by MTT, flow cytometry, and migration assays. In vivo targeting of CK2alpha/alpha' in HNSCC xenograft models was achieved using anti-CK2alpha/alpha' oligodeoxynucleotide encapsulated in sub-50-nm tenfibgen nanocapsules. RESULTS:CK2 subunit proteins were overexpressed in HNSCC lines and tissues. Knockdown of CK2 subunits differentially inhibited IkappaBalpha degradation, NF-kappaB nuclear localization, phosphorylation, DNA binding, and reporter activity. CK2 subunits modulated gene expression and the malignant phenotype involved in cell cycle and migration, whereas CK2alpha is critical to promote proliferation, antiapoptosis, and cisplatin resistance in vitro. Furthermore, in vivo delivery of anti-CK2alpha/alpha' oligodeoxynucleotide nanocapsules significantly suppressed tumor growth in HNSCC xenograft models, in association with modulation of CK2 and NF-kappaB regulated molecules, TP53 family proteins, and induction of apoptosis. CONCLUSIONS: Our study reveals a novel role of CK2 in coregulating NF-kappaB activation, TP53/p63 expression, and downstream gene expression. Downregulation of CK2 in HNSCC models in vitro and in vivo shows antitumor effects as well as sensitization to cisplatin.
Authors: D M Keller; X Zeng; Y Wang; Q H Zhang; M Kapoor; H Shu; R Goodman; G Lozano; Y Zhao; H Lu Journal: Mol Cell Date: 2001-02 Impact factor: 17.970
Authors: S Saha; A Bardelli; P Buckhaults; V E Velculescu; C Rago; B St Croix; K E Romans; M A Choti; C Lengauer; K W Kinzler; B Vogelstein Journal: Science Date: 2001-10-11 Impact factor: 47.728
Authors: E Landesman-Bollag; R Romieu-Mourez; D H Song; G E Sonenshein; R D Cardiff; D C Seldin Journal: Oncogene Date: 2001-05-31 Impact factor: 9.867
Authors: Janeen H Trembley; Zhong Chen; Gretchen Unger; Joel Slaton; Betsy T Kren; Carter Van Waes; Khalil Ahmed Journal: Biofactors Date: 2010 May-Jun Impact factor: 6.113
Authors: Shijun Zhu; Terry W Moore; Xiaoqian Lin; Nao Morii; Alessandra Mancini; Randy B Howard; Deborah Culver; Richard F Arrendale; Prabhakar Reddy; Taylor J Evers; Hongzheng Zhang; Gabriel Sica; Zhuo G Chen; Aiming Sun; Haian Fu; Fadlo R Khuri; Dong M Shin; James P Snyder; Mamoru Shoji Journal: Integr Biol (Camb) Date: 2012-04-25 Impact factor: 2.192
Authors: Xinping Yang; Hai Lu; Bin Yan; Rose-Anne Romano; Yansong Bian; Jay Friedman; Praveen Duggal; Clint Allen; Ryan Chuang; Reza Ehsanian; Han Si; Satrajit Sinha; Carter Van Waes; Zhong Chen Journal: Cancer Res Date: 2011-05-15 Impact factor: 12.701
Authors: Janeen H Trembley; Gretchen M Unger; Vicci L Korman; Diane K Tobolt; Zygmunt Kazimierczuk; Lorenzo A Pinna; Betsy T Kren; Khalil Ahmed Journal: Cancer Lett Date: 2011-10-12 Impact factor: 8.679
Authors: Gretchen M Unger; Betsy T Kren; Vicci L Korman; Tyler G Kimbrough; Rachel I Vogel; Frank G Ondrey; Janeen H Trembley; Khalil Ahmed Journal: Mol Cancer Ther Date: 2014-05-27 Impact factor: 6.261
Authors: Janeen H Trembley; Gretchen M Unger; Diane K Tobolt; Vicci L Korman; Guixia Wang; Kashif A Ahmad; Joel W Slaton; Betsy T Kren; Khalil Ahmed Journal: Mol Cell Biochem Date: 2011-07-15 Impact factor: 3.396
Authors: Claire M Cannon; Janeen H Trembley; Betsy T Kren; Gretchen M Unger; M Gerard O'Sullivan; Ingrid Cornax; Jaime F Modiano; Khalil Ahmed Journal: Hum Gene Ther Clin Dev Date: 2017-03-23 Impact factor: 5.032